These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28661909)

  • 1. Increased Risk of Bleeding in Left Ventricular Assist Device Patients Treated with Enoxaparin as Bridge to Therapeutic International Normalized Ratio.
    Bhatia A; Juricek C; Sarswat N; Adatya S; Kim G; Sayer G; Ota T; Jeevanandam V; Uriel N
    ASAIO J; 2018; 64(2):140-146. PubMed ID: 28661909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enoxaparin Use and Adverse Events in Outpatients With a Continuous Flow Left Ventricular Assist Device at a Single Institution.
    Bernard AM; Alvarez PA; Bream-Rouwenhorst HR; Horner KE; Briasoulis A; Czerniak LC
    J Pharm Pract; 2022 Jun; 35(3):422-426. PubMed ID: 33648405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Outcomes of Enoxaparin Bridge Therapy in HeartMate II versus HeartWare HVAD Recipients.
    Patel M; Ahuja T; Arnouk S; Gidea C; Reyentovich A; Smith DE; Moazami N; Papadopoulos J; Lewis TC
    J Cardiovasc Pharmacol Ther; 2021 Sep; 26(5):473-479. PubMed ID: 33844604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.
    Bui HT; Krisnaswami A; Le CU; Chan J; Shenoy BN
    Am J Cardiol; 2009 Nov; 104(10):1429-33. PubMed ID: 19892063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of enoxaparin as bridge to therapeutic INR after LVAD implantation.
    Shah Z; Mastoris I; Acharya P; Rali AS; Mohammed M; Sami F; Ranka S; Wagner S; Zanotti G; Salerno CT; Haglund NA; Sauer AJ; Ravichandran AK; Abicht T
    J Cardiothorac Surg; 2020 Nov; 15(1):329. PubMed ID: 33189134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study.
    Dentali F; Pignatelli P; Malato A; Poli D; Di Minno MN; Di Gennaro L; Rancan E; Pastori D; Grifoni E; Squizzato A; Siragusa S; Di Minno G; Ageno W
    Am J Hematol; 2012 Apr; 87(4):384-7. PubMed ID: 22367852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device.
    John R; Kamdar F; Liao K; Colvin-Adams M; Miller L; Joyce L; Boyle A
    J Thorac Cardiovasc Surg; 2008 Nov; 136(5):1318-23. PubMed ID: 19026822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices.
    Nassif ME; LaRue SJ; Raymer DS; Novak E; Vader JM; Ewald GA; Gage BF
    Circ Heart Fail; 2016 May; 9(5):. PubMed ID: 27154497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bridging with enoxaparin using a half-therapeutic dose regimen: safety and efficacy.
    Klamroth R; Gottstein S; Essers E; Landgraf H
    Vasa; 2010 Aug; 39(3):243-8. PubMed ID: 20737383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Half-dose enoxaparin vs. full-dose enoxaparin for postoperative bridging therapy in patients after cardiac surgery: which dose regimen should be preferred?
    Weiss A; Brose S; Ploetze K; Matschke K
    Clin Hemorheol Microcirc; 2013 Jan; 54(3):249-58. PubMed ID: 23648452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of enoxaparin for bridging of warfarin in outpatients with left ventricular assist devices (LVADs).
    Hiruy A; Anderson K; Bhattacharya S; Lee R; Williams JB
    Artif Organs; 2024 Apr; 48(4):386-391. PubMed ID: 37990598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of anticoagulation and nonsurgical major bleeding in recipients of continuous-flow left ventricular assist devices.
    Veasey TM; Floroff CK; Strout SE; McElray KL; Brisco-Bacik MA; Cook JL; Toole JM; Craig ML; Van Bakel AB; Meadows HB; Uber WE
    Artif Organs; 2019 Aug; 43(8):736-744. PubMed ID: 30868618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulation management following left ventricular assist device implantation is similar across all provider strategies.
    McDavid A; MacBrair K; Emani S; Yu L; Lee PHU; Whitson BA; Lampert BC; Agarwal R; Kilic A
    Interact Cardiovasc Thorac Surg; 2018 Jan; 26(1):60-65. PubMed ID: 29049614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation.
    Sandner SE; Riebandt J; Haberl T; Mahr S; Rajek A; Schima H; Wieselthaler GM; Laufer G; Zimpfer D
    J Heart Lung Transplant; 2014 Jan; 33(1):88-93. PubMed ID: 24239003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective analysis of bleeding events in left ventricular assist device patients.
    Sherazi S; Kouides P; Francis C; Lowenstein CJ; Refaai M; Conley G; Johnson BA; Muchnik E; Lien S; Massey HT; Alexis JD
    Int J Artif Organs; 2018 May; 41(5):269-276. PubMed ID: 29562808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran etexilate as second-line therapy in patients with a left ventricular assist device.
    Terrovitis JV; Ntalianis A; Kapelios CJ; Vakrou S; Diakos N; Katsaros L; Tsamatsoulis M; Kaldara E; Charitos C; Nanas JN
    Hellenic J Cardiol; 2015; 56(1):20-5. PubMed ID: 25701968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulation Bridging in Patients With Left Ventricular Assist Device: A Regional Analysis of HeartMate 3 Recipients.
    Yaranov DM; Baldridge AS; Gonzalez M; Biglane JB; Tanaka D; Fischer W; Larkin C; Ullah R; Chaudhry SP; Pham DT
    ASAIO J; 2024 Feb; 70(2):93-98. PubMed ID: 37862687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased incidence of gastrointestinal bleeding following implantation of the HeartMate II LVAD.
    Stern DR; Kazam J; Edwards P; Maybaum S; Bello RA; D'Alessandro DA; Goldstein DJ
    J Card Surg; 2010 May; 25(3):352-6. PubMed ID: 20331479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of CHA2DS2-VASc and HAS-BLED Scores as Predictor of Thromboembolism and Bleeding After Left Ventricular Assist Device Implantation.
    Kemal HS; Ertugay S; Nalbantgil S; Ozturk P; Engin C; Yagdi T; Ozbaran M
    ASAIO J; 2017; 63(6):720-724. PubMed ID: 28187048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures.
    Hammerstingl C; Omran H;
    Thromb Haemost; 2009 Jun; 101(6):1085-90. PubMed ID: 19492151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.